Cardiac ArrythmiasNCT02741180
Sparsity-based Magnetic Resonance Imaging of Cardiac Arrhythmias
A study testing 3D Imaging and Late Gadolinium Enhancement (LGE) in people with Cardiac Arrythmias, run by NYU Langone Health at 1 site in United States.
Trial summary
The primary purpose of this study is to improve the quality of Magnetic Resonance Imaging in patients with heart arrhythmia. Investigators will recruit 105 patients with arrhythmia and 30 control volunteers over 3 years and will use two arrhythmia-tolerant imaging methods for diagnosis. Read more about this study
- Who is it for?
- Ages 10 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Cardiac Arrythmias
- What is being tested?
- 3D Imaging and Late Gadolinium Enhancement (LGE)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 135 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Apr 2025to Aug 2027
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 10 to 85 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Patients diagnosed with heart arrhythmia scheduled for routine clinical MRI examinations).
- Patients scheduled for routine clinical MRI examinations who do not have a specific known diagnosis of arrhythmia, but who may be found to have image degradation due to arrhythmia during the CMR examination.
- No history of heart arrhythmia.
Who cannot join
- Hemodynamic instability.
- Contraindications for MRI examinations (e.g., pacemakers or ferromagnetic vascular clips).
- History of prior cardiovascular disease or significant risk factors:
- Diabetes, hypertension, smoking, and hyperlipidemia, etc.
Trial locations and contacts
1 site in 1 country.
United States1 site
New York University School of Medicine
New York, New York, 10016
About this study
The primary purpose of this study is to improve the quality of Magnetic Resonance Imaging in patients with heart arrhythmia. Investigators will recruit 105 patients with arrhythmia and 30 control volunteers over 3 years and will use two arrhythmia-tolerant imaging methods for diagnosis.
Read the detailed description
In the proposed research, investigators will extend conventional cardiac magnetic resonance methods to enable the creation of high-quality cine CMR images in the presence of multiple kinds of arrhythmia. Two arrhythmia-tolerant imaging methods will be adopted, which are particularly useful in arrhythmia: 1) 3D imaging, which is useful for many purposes, including "road mapping" of electrophysiology (EP) procedures, and 2) late gadolinium enhancement (LGE), which is useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
- Conditions
- Cardiac Arrythmias
- Being tested
- 3D Imaging, Late Gadolinium Enhancement (LGE)
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
3D ImagingOther
"roadmapping" of electrophysiology (EP) procedures
Late Gadolinium Enhancement (LGE)Other
useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
| Study group | Role | What they receive |
|---|---|---|
| Patients with Arrhythmias | Other | Not described Receives: Other: 3D Imaging; Other: Late Gadolinium Enhancement (LGE) |
| Healthy Control | Other | Not described Receives: Other: 3D Imaging; Other: Late Gadolinium Enhancement (LGE) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Paired-sample Wilcoxon signed rank test to evaluate measures on Likert scales
Measured: 3 Years
Paired-sample t tests for quantitative measures of intensity of image artifacts
Measured: 3 Years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Apr 2016 (estimated)
- Study start23 Apr 2025
- Primary completionAug 2027 (estimated)
- Study completionAug 2027 (estimated)
Why it stopped: COVID-19
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cardiac ArrythmiasStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 135 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Leon Axel, MD, Principal investigator, New York University Medical School
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02741180
- Sponsor's protocol ID
- 15-00116
- Status last verified
- Mar 2026
- First submitted
- 29 Mar 2016
- Last updated
- 3 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Sparsity-based Magnetic Resonance Imaging of Cardiac Arrhythmias
- ClinicalTrials.gov ID
- NCT02741180
- Acronym / sponsor ID
- 15-00116
- Conditions
- Cardiac Arrythmias
- Study type
- Interventional
- Recruitment status
- SuspendedReason stopped: COVID-19
- Enrolment
- 135 participants (estimated)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Study start
- 23 Apr 2025 (actual)
- Primary completion
- Aug 2027 (estimated)
- Study completion
- Aug 2027 (estimated)
- First posted
- 18 Apr 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary purpose of this study is to improve the quality of Magnetic Resonance Imaging in patients with heart arrhythmia. Investigators will recruit 105 patients with arrhythmia and 30 control volunteers over 3 years and will use two arrhythmia-tolerant imaging methods for diagnosis.
Detailed description
In the proposed research, investigators will extend conventional cardiac magnetic resonance methods to enable the creation of high-quality cine CMR images in the presence of multiple kinds of arrhythmia. Two arrhythmia-tolerant imaging methods will be adopted, which are particularly useful in arrhythmia: 1) 3D imaging, which is useful for many purposes, including "road mapping" of electrophysiology (EP) procedures, and 2) late gadolinium enhancement (LGE), which is useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with Arrhythmias | Other | Other: 3D Imaging, Other: Late Gadolinium Enhancement (LGE) |
| Healthy Control | Other | Other: 3D Imaging, Other: Late Gadolinium Enhancement (LGE) |
Who may qualify
- Ages
- 10 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- Patients diagnosed with heart arrhythmia scheduled for routine clinical MRI examinations).
- Patients scheduled for routine clinical MRI examinations who do not have a specific known diagnosis of arrhythmia, but who may be found to have image degradation due to arrhythmia during the CMR examination.
- No history of heart arrhythmia.
Key exclusion criteria (4 listed)
- Hemodynamic instability.
- Contraindications for MRI examinations (e.g., pacemakers or ferromagnetic vascular clips).
- History of prior cardiovascular disease or significant risk factors:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 3D Imaging"roadmapping" of electrophysiology (EP) procedures | Other | Healthy Control, Patients with Arrhythmias |
| Late Gadolinium Enhancement (LGE)useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias. | Other | Healthy Control, Patients with Arrhythmias |
Primary outcome
Paired-sample Wilcoxon signed rank test to evaluate measures on Likert scales
Time frame: 3 Years
Paired-sample t tests for quantitative measures of intensity of image artifacts
Time frame: 3 Years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Apr 2026.
Related trials for Cardiac Arrythmias
RecruitingObservational study
RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)
Cardiac Arrythmias
RecruitingObservational study
Quality of Life Before and After Transcatheter Ablation in Children With Arrythmias
Arrhythmia
RecruitingObservational study
Tezspire Cardiac Events PASS
Cardiovascular Events, MACE
Not yet recruiting
Assessment of Heart Rate Variability HRV During Descent DE From 2850m to Sea Level and During Re-ascent A From Sea Level to 2850m in Patients With Pulmonary Arterial Hypertension PAH
High Altitude Effects, High Altitude
Recruiting
Agilis RF TSP Early Feasibility Study
Cardiac Arrythmias, Left Atrial Appendage Closure
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Leon Axel, MD principal investigator
New York University Medical School
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 3D Imaging and Late Gadolinium Enhancement (LGE) in people with Cardiac Arrythmias, run by NYU Langone Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: paused, as of the sponsor's last update on 3 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Paired-sample Wilcoxon signed rank test to evaluate measures on Likert scales (time frame: 3 Years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Apr 2026.